Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Terminated 2Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Solid Tumours 5Melanoma 5Neurofibromatosis 1 4Lung Neoplasms 4Rectal Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Colonic Neoplasms 3Breast Neoplasms 3Biliary Tract Neoplasms 3Neurofibroma, Plexiform 2Uveal Melanoma 1Solid Tumors 1Renal Insufficiency 1Primary Myelofibrosis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Muscle Invasive Bladder Cancer 1Locally Advanced or Metastatic Solid Tumors 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Kidney Neoplasms 1Healthy Volunteers Pharmacokinetic Study 1Gallbladder Neoplasms 1Disease Progression 1Cholangiocarcinoma 1Advanced Non Small Cell Lung Cancer 1Advanced Cancer 1Adult Solid Neoplasm 1

Interventions

Fluorouracil 38Capecitabine 31Oxaliplatin 30Leucovorin 30Radiotherapy 21Irinotecan 20Bevacizumab 15Radiation 12Cetuximab 12pembrolizumab 9Gemcitabine 7trifluridine tipiracil drug combination 5dehydroftorafur 5cediranib 5Radiotherapy, Intensity-Modulated 5Folfox protocol 5Erlotinib Hydrochloride 5Cisplatin 5Carboplatin 5trametinib 4Surgical Procedures, Operative 4Paclitaxel 4Neoadjuvant Therapy 4Gene Expression Profiling 4Cyclophosphamide 4sargramostim 3binimetinib 3Trifluridine 3Sorafenib 3Pemetrexed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Rectal Neoplasms × AZD 6244 × Clear all
NCT01160926 2023-04-24

DREAMtherapy

The Christie NHS Foundation Trust

Phase 1 Terminated
31 enrolled
Gastrointestinal

Rectal Neoplasms

NCT01134601 2021-12-01

A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
1 enrolled 7 charts
Gastrointestinal

Rectal Neoplasms

NCT01217450 2014-05-29

Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
33 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡